Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Treatment Strategy of Iparomlimab and Tuvonralimab Plus Chemotherapy for Inducing Conversion to Resectability in Initially Unresectable Stage III Non-Small Cell Lung Cancer: A Single-Arm Phase II Clinical Study

NCT07139041 is registered in ClinicalTrials.gov with Chang Chen as lead sponsor.

NCT NCT07139041
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07139041 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Treatment Strategy of Iparomlimab and Tuvonralimab Plus Chemotherapy for Inducing Conversion to Resectability in Initially Unresectable Stage III Non-Small Cell Lung Cancer: A Single-Arm Phase II Clinical Study
Lead sponsor
Chang Chen
Phase
Phase 2
Overall status
Not yet recruiting
Start date
October 31, 2025
Completion date
June 30, 2029
Enrollment
69 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

nsclc (non-small-cell lung cancer)